Immunity to stemness genes in human cancer.
A growing body of data points to not only intraclonal heterogeneity and hierarchy of growth potential, but also plasticity of cellular differentiation within human tumors. Recent studies have also identified surprising overlap between pathways that regulate pluripotency in embryonal stem (ES) cells and oncogenesis. While there is a long history of targeting embryonal tissues toward cancer vaccines, recent identification of crucial stemness pathways in ES cells as well as putative cancer stem cells (CSCs) provides novel opportunities for antigen-specific targeted therapy. Here we discuss recent insights into the capacity of the immune system to target these pathways. Immunologic targeting of pathways associated with stemness has implications for both immune regulation of tumor growth as well as regenerative therapies with embryonal stem cells.
Dhodapkar
Madhav V
MV
Section of Hematology, Yale University, New Haven, CT 06510, USA. madhav.dhodapkar@yale.edu
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines; D002454:Cell Differentiation; D053595:Embryonic Stem Cells / Q000276:immunology*; D006801:Humans; D007109:Immunity; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D014411:Neoplastic Stem Cells / Q000276:immunology*; D009857:Oncogenes / Q000276:immunology; D044968:Regenerative Medicine
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines